The protocol for TIM has been deposited in protocols.io and may be accessed at <http://dx.doi.org/10.17504/protocols.io.bdcki2uw>. All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

The green alga *Chlamydomonas reinhardtii* provides an excellent model system for the study of cilia/flagella, cell cycle, photosynthesis, and mitochondria \[[@pone.0232594.ref001], [@pone.0232594.ref002]\]. A commonly used method for the generation of mutants in this organism is insertional mutagenesis \[[@pone.0232594.ref003]--[@pone.0232594.ref006]\]. This method relies on the transformation of *C*. *reinhardtii* strains with exogenous double-stranded DNA (commonly an antibiotic-resistance gene) that integrates randomly into the genome, causing a mutation at the insertion site. The integrated exogenous DNA confers antibiotic resistance, which facilitates screening of transformants and identification of the gene containing the insertion \[[@pone.0232594.ref007]--[@pone.0232594.ref010]\]. Rescue of insertional mutants with genetically engineered constructs then allows interrogation of specific residues, domains, etc.

Recently, a genome-wide mutant library for *C*. *reinhardtii* was developed using insertional mutagenesis \[[@pone.0232594.ref008], [@pone.0232594.ref011]\]. While this has broadly benefited genetic analysis in this organism, several drawbacks exist. First, the project has not yet achieved universal coverage of the genome. Second, some genes only have insertions in non-coding regions which may not result in a null mutation, complicating downstream analyses. Third, the mutants were created using a strain that has impaired motility and lacks a cell wall, which reduces plating efficiencies and precludes isolation of highly pure flagella. Finally, for some experiments there may be a need to have mutations in a different genetic background, or double mutants, either of which would require extensive genetic crossing to accomplish.

The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system has greatly facilitated our ability to edit genomes in many organisms \[[@pone.0232594.ref012], [@pone.0232594.ref013]\]. The first report using CRISPR/Cas9 in *C*. *reinhardtii* demonstrated that Cas9 and a single guide RNA expressed from a plasmid electroporated into a strain lacking a cell wall was active, but only a single stable transformant with a deletion consistent with Cas9 editing was obtained from an initial pool of 1.6X10^9^ cells \[[@pone.0232594.ref014]\]. This raised concerns that Cas9 was toxic in *C*. *reinhardtii*. More recent studies, exploring different approaches, have clearly demonstrated that CRISPR/Cas9 is useful for targeted disruption of genes in *C*. *reinhardtii* \[[@pone.0232594.ref015]--[@pone.0232594.ref022]\]. However, some of the published methods have low efficiencies of achieving the desired edit, making it laborious to identify cells in which a gene has been successfully targeted, especially in the absence of a selectable marker. Additionally, some methods can be applied only to certain genes or strains.

To establish a universal, highly efficient, and relatively simple CRISPR/Cas9-based gene-editing protocol for targeted disruption of genes, we started with the method of Shamoto et al. \[[@pone.0232594.ref023]\], who briefly described a protocol in which about 55% of picked colonies had insertional mutations in the targeted gene. This is an efficiency that, as far as we know, is higher than any previously reported. To understand which aspects of the protocol are critical for achieving such efficiency, and whether the protocol could be further improved, we first reproduced their results. We then carried out a series of pair-wise experiments; in each experiment, a single parameter was varied, the results assessed, and any perceived improvement incorporated into the working protocol. Our aim was not to achieve statistical significance for any one variable, but to define the important conditions enabling a simple, reliable, flexible, and robust method for targeted insertional mutagenesis, which we term TIM. As we demonstrate below, TIM is applicable to cell-walled *C*. *reinhardtii* strains, can be applied to cells grown on agar plates or in liquid medium, can utilize different antibiotic-resistant selectable markers, works with electroporation or the glass-bead method for delivery of macromolecules into the cells, yields mutation efficiencies as high as 90%, and even can be used to generate double mutants. We have used the TIM method to target six different genes, and in each case we achieved a high rate of mutagenesis. Thus, the method promises to be effective for many, if not all, non-essential nuclear genes.

Results {#sec002}
=======

In the TIM method ([Fig 1](#pone.0232594.g001){ref-type="fig"}), *C*. *reinhardtii* cells are treated with autolysin to remove their cell walls. A Cas9-guide RNA (gRNA) ribonucleoprotein (RNP) together with exogenous double-stranded (donor) DNA containing gene-specific homology arms and an integral antibiotic-resistance gene are then delivered to the cells using electroporation or the glass-bead method. The RNP generates a double-strand break (DSB) at the target site, which facilitates insertion of the exogenous DNA at that site (although insertions can occur randomly in other regions of the genome as well). If the antibiotic-resistance gene remains intact, the insertion confers antibiotic resistance to the cells. The insertion may be accompanied by concatenation of the cassette, deletion of genomic DNA, or reorganizations of the target site, all of which are common to insertional mutagenesis techniques \[[@pone.0232594.ref006]\]. Alterations resulting from insertion at the target site are then easily identified by PCR, with the mutation rate calculated as the number of colonies carrying an insertion at the target site divided by the total number of drug-resistant colonies picked for analysis.

![An overview of the TIM (targeted insertional mutagenesis) method.\
(A) Schematic overview of TIM. Following delivery of Cas9/gRNA RNP and double-stranded donor DNA (antibiotic-resistance cassette) into cells by electroporation or the glass-bead method, the RNP causes a double-stranded break (DSB) at the target site (blue box). DSBs are repaired with or without integration of the donor DNA. The left pathway results in insertional mutations, whereas the right pathway may generate insertion/deletion (indel) mutations (small white box within blue box, third row). As with other insertional mutagenesis approaches, donor DNA also can insert randomly in the genome, resulting in antibiotic-resistant cells that may not have a mutation at the target site. Cells are then selected for presence of the donor DNA via growth on antibiotic-specific media. Finally, antibiotic-resistant cells are screened via PCR to identify cell lines with mutations at the target site. L and R, left and right homology arms of the donor DNA, or genomic regions corresponding to left and right homology arms of the donor DNA. Short black arrows (P1, P2) indicate the primers used for screening. In the typical agarose gel shown (in this case, the targeted gene was *FAP70*), the asterisk and arrowhead on the right side of the gel indicate positive control (in this case *FUS1*) and wild-type target-specific PCR bands, respectively. Absence of a wild-type target-specific band indicates a mutation at the target site; in most cases here this is accompanied either by the appearance of an \~2-Kb band (arrow on the right side of the gel), suggesting insertion of a single copy of the antibiotic-resistance gene (\~1.7 Kb), or by lack of any detectible gene-specific band, suggesting a large insertion/deletion at the target site. Presence of a wild-type target-specific band indicates that the cell line was not mutated at the target site; the antibiotic-resistance gene has inserted into the genome somewhere other than at the target site. Mutants generated by the right-hand pathway (no insertion of donor DNA) would not be selected for unless the donor DNA inserted into another site; in the latter case, mutants with small indels would appear to be wild type in the PCR screen because the PCR product would be at or near wild-type length. Relative to the target site, the exact positions of the primers and of genomic regions corresponding to the homology arms will vary when targeting different genes. (B) Schematic of the antibiotic-resistance cassettes used. Gene-specific homology arms of varying lengths were added to the 5'- and 3'-ends of these cassettes. (C) Representative western blot of whole-cell extracts of g1 (wild type) and an *ift81* mutant generated by TIM. Absence of an IFT81 band in the mutant strain confirms disruption of the *IFT81* gene. ATP synthase β subunit (βF1 ATPase) was probed as a loading control.](pone.0232594.g001){#pone.0232594.g001}

Shamoto et al. \[[@pone.0232594.ref023]\] did not specify the conditions used to grow the cells in their experiment, but correspondence with them established that growth was on agar plates in continuous light. Initially, we duplicated their method by targeting exon 2 of *FAP70* in strain CC-125 (137c), which they used, and in strain CC-5415 (g1) \[[@pone.0232594.ref024]\]; both of these strains have cell walls. In four different experiments, we achieved mutation efficiencies of 42% and 40% for 137c and 50% and 62% for g1 ([Table 1](#pone.0232594.t001){ref-type="table"}, rows 1--4). These results are consistent with the 55% mutation rate reported by Shamoto and colleagues. Therefore, it is likely that TIM also will work well with other strains. Our subsequent experiments were carried out using the g1 strain.

10.1371/journal.pone.0232594.t001

###### Summary of experiments and results[\*](#t001fn001){ref-type="table-fn"}.

![](pone.0232594.t001){#pone.0232594.t001g}

  Row   Parameters                                        Conditions[^†^](#t001fn002){ref-type="table-fn"}   Mutation efficiency (\# mutant colonies/\# of colonies screened)                 
  ----- ------------------------------------------------- -------------------------------------------------- ------------------------------------------------------------------ ------------- -----------
  1     Cell line[^‡^](#t001fn003){ref-type="table-fn"}   137c                                               42% (40/96)                                                                      
  2     137c                                              40% (37/94)                                                                                                                         
  3     g1                                                50% (45/90)                                                                                                                         
  4     g1                                                62% (60/96)                                                                                                                         
  5     Light:dark cycle                                  14 h light:10 h dark cycle                         96% (46/48)                                                        85% (39/46)   
  6     Liquid culture cell density                       6.6E5                                              48% (22/46)                                                                      
  7     3.2E6                                             38% (18/48)                                                                                                                         
  8     3.84E6                                            70% (32/46)                                                                                                                         
  9     2.36E6                                            36% (16/45)                                                                                                                         
  10    4.56E6                                            67% (31/46)                                                                                                                         
  11    1.33E7                                            64% (30/47)                                                                                                                         
  12    Autolysin treatment                               No                                                 3% (1/40)                                                                        
  13    Yes                                               87% (41/47)                                                                                                                         
  14    Homology arm length                               50 bp                                              85% (39/46)                                                        67% (32/48)   
  15    25 bp                                             76% (34/45)                                        63% (30/48)                                                                      
  16    0 bp                                                                                                 42% (20/48)                                                                      
  17    Selectable marker cassette                        Paromomycin                                        78% (36/46)                                                                      
  18    Hygromycin                                        84% (38/45)                                                                                                                         
  19    gRNA quality                                      Freshly made                                       87% (41/47)                                                                      
  20    Frozen and thawed                                 49% (23/47)                                                                                                                         
  21    Cell density during electroporation               3.50E7 cells/ul                                    68% (32/47)                                                                      
  22    1.76E8 cells/ul                                   87% (41/47)                                                                                                                         
  23    Delivery of RNP and donor DNA                     Electroporation                                    87% (41/47)                                                                      
  24    Glass beads                                       47% (21/45)                                                                                                                         
  25    Gene plus gRNA and cassette design                IFT81 gRNA 1                                       42% (19/45)                                                        36% (16/45)   
  26    FAP70                                             85% (39/46)                                        67% (32/48)                                                                      
  27    IFT81 gRNA 2                                      40% (19/48)                                                                                                                         
  28    FAP70                                             63% (30/48)                                                                                                                         
  29    IFT81 gRNA 1                                      30% (14/47)                                                                                                                         
  30    IFT81 gRNA 2                                      52% (24/46)                                                                                                                         
  31    MOT17                                             93% (41/44)                                                                                                                         
  32    CDPK13                                            47% (20/43)                                                                                                                         
  33    FAP70                                             78% (36/46)                                                                                                                         
  34    CEP131 gRNA-1 no homology arms                    41% (19/46)                                                                                                                         
  35    CEP131 gRNA-2 no homology arms                    30% (14/46)                                                                                                                         
  36    IFT43 no homology arms                            89% (40/45)                                                                                                                         
  37    Double mutations                                  IFT81 PARO/ FAP70 HYG                              15% (6/40)                                                         3% (1/38)     6% (3/48)

\*Experiments in the same color are comparable with only one parameter changed between them.

^†^Except as noted, all experiments used autolysin treatment followed by electroporation to deliver the RNP and donor DNA with homology arms into the cells.

^‡^For these experiments only, cells were grown in continuous light.

Cultures grown in continuous light are likely to contain cells in various phases of the cell cycle, only one of which may be favorable to achieving high mutation rates. To determine if this is a critical parameter, we grew g1 cells on a 14 h light:10 h dark cycle and targeted the *FAP70* gene during the middle of the light cycle. In two separate experiments, we obtained mutation efficiencies of 96% and 85% ([Table 1](#pone.0232594.t001){ref-type="table"}, row 5). Therefore, cells grown synchronously and used in the middle of the light cycle yield efficiencies at least as high as those grown on continuous light. Subsequent experiments were carried out using cells grown on this light: dark cycle.

To determine if growth on agar plates was a stringent parameter for efficient mutagenesis, we grew cells in liquid TAP medium with shaking for two days. In each of two experiments, we inoculated flasks with three different concentrations of cells so that the cultures would have different cell densities (ranging from 6.6X10^5^ to 1.3X10^7^ cells/mL) when harvested for mutagenesis. The resulting mutagenesis rates varied from 36% to 70%, with slightly higher mutagenesis rates for cells harvested at densities of about 3.8X10^6^ cells/mL or higher ([Table 1](#pone.0232594.t001){ref-type="table"}, rows 6--11). Therefore, TIM is efficient with cells grown on agar plates or in liquid culture, and culture cell density does not appear to be critical within the range tested. However, harvesting cells grown on agar plates was easier, so we used this manner of growth in all other experiments reported here.

Removal of the cell wall prior to transformation of cell-walled cells with plasmids by electroporation is not necessary \[e.g., [@pone.0232594.ref025]--[@pone.0232594.ref027]\]. To determine if cell-wall removal is required for delivery of RNPs into cells by electroporation during TIM, we targeted *FAP70* in g1 cells treated with and without autolysin. In the absence of autolysin treatment, we achieved only a 3% mutation rate, versus an 87% mutation rate for the autolysin-treated cells ([Table 1](#pone.0232594.t001){ref-type="table"}, rows 12--13). Therefore, cell-wall removal is critical for efficient mutagenesis using the TIM method. In all experiments presented here, except that of row 12, the efficiency of cell-wall removal was \~50% or greater. In addition, in all paired experiments, the same batch of autolysin-treated cells was utilized for both experiments.

Shamoto et al. \[[@pone.0232594.ref023]\] used donor DNA containing gene-specific homology arms of 50 bp, reasoning that this would increase the likelihood of insertion of the antibiotic-resistance cassette at the target site. To determine how the length of the homology arms affects mutation efficiency, we targeted *FAP70* using donor DNA with 50-bp and 25-bp homology arms. In two separate tests, we achieved 85% and 67% mutation rates for donor DNA with 50-bp homology arms vs. 76% and 63% for donor DNA with 25-bp homology arms ([Table 1](#pone.0232594.t001){ref-type="table"}, rows 14 and 15). In the second of the above experiments, we further compared donor DNA completely lacking homology arms, which yielded a 42% mutation rate ([Table 1](#pone.0232594.t001){ref-type="table"}, row 16). Therefore, the presence of homology arms appears to be beneficial, but the homology arms are not absolutely required for efficient mutagenesis.

Shamoto et al. \[[@pone.0232594.ref023]\] used an antibiotic-resistance cassette containing the *Streptomyces rimosus aphVIII* gene and selected for insertional mutants using paromomycin. To determine if choice of antibiotic-resistance gene affects mutation efficiency, we compared donor DNAs containing the *aphVIII* gene vs. the *aph7"* gene from *S*. *hygroscopicus* conferring hygromycin resistance ([Fig 1B](#pone.0232594.g001){ref-type="fig"}). We achieved a 78% mutation rate using the former, compared to 84% with the latter ([Table 1](#pone.0232594.t001){ref-type="table"}, rows 17 and 18). These data indicate that the high mutation efficiency of TIM is not dependent on use of a specific antibiotic-resistance gene and suggests that investigators may be able to use a variety of selectable markers with a high degree of success.

To determine how handling and storage of the gRNA affected mutation rate, we carried out an experiment in which we targeted *FAP70* with fresh gRNA vs. gRNA that had undergone several freeze/thaw cycles. We obtained mutation rates of 87% and 49% respectively ([Table 1](#pone.0232594.t001){ref-type="table"}, rows 19 and 20), underscoring the importance of using fresh gRNA to achieve maximum efficiency.

Shamoto et al. \[[@pone.0232594.ref023]\] provided no recommendation on cell density during electroporation. To determine if this was an important variable, we targeted *FAP70* by electroporation at cell densities in the cuvette of 3.5X10^7^ and 1.8X10^8^ cells/ml and obtained mutagenesis rates of 68% and 87%, respectively ([Table 1](#pone.0232594.t001){ref-type="table"}, rows 21 and 22). Therefore, efficient mutagenesis can be obtained at cell densities over at least the five-fold range tested. In subsequent experiments, we used cell densities that we estimated to be near the upper limit of that range.

All of the above experiments were carried out by delivering the gRNA and donor DNA to the cells by electroporation. However, not all labs have access to an electroporator, and it may not be possible to exactly match electroporation conditions with electroporators from different manufacturers. An alternative, and widely used, method for delivery of macromolecules into *C*. *reinhardtii* cells is the glass-bead method \[[@pone.0232594.ref028]\]. To determine how the efficiency of TIM is affected by the method of delivery, we carried out an experiment comparing electroporation to a slightly modified version of the glass-bead method. Targeting *FAP70*, we achieved an 87% mutation rate with the former and a 47% mutation rate with the latter ([Table 1](#pone.0232594.t001){ref-type="table"}, rows 23 and 24). Therefore, although the efficiency with the glass-bead method may be lower than with electroporation, the glass-bead method provides a second, highly economical, method for TIM when electroporation is not readily available.

To clarify the types of mutations created by TIM, we randomly selected seven *fap70* mutant strains that appeared to have \~2-kb bands when the target site was screened by PCR ([Fig 1A](#pone.0232594.g001){ref-type="fig"}). These mutant strains were generated using donor DNA containing the paromomycin-resistance cassette and 50-bp homology arms. In wild type, sequence corresponding to the left homology arm was 27 bps upstream of the protospacer adjacent motif (PAM); sequence corresponding to the right homology arm was 3 bps downstream from the PAM. DNA from the PCR bands was purified, sequenced ([S1 Appendix](#pone.0232594.s001){ref-type="supplementary-material"}), and aligned with donor DNA and wild-type sequences ([S2 Appendix](#pone.0232594.s002){ref-type="supplementary-material"}). The sequences from five of the strains (C1, C2, C3, D1, and D4) were the same as that of wild type except that the 33 bps between the sequences corresponding to the homology arms were replaced with sequence corresponding to an intact paromomycin-resistance cassette, as expected from homology-directed repair (HDR). The 5' end of the sequence from strain C6 matched that of wild type until 2 bps upstream of the PAM, at which point a partial cassette, immediately preceded by a C, was inserted. Compared to an intact cassette, this partial cassette lacked the first 167 bps at the 5' end of the cassette, as well as the last 165 bps at the 3' end of the cassette, downstream of the *COP1*-3'-UTR ([Fig 1B](#pone.0232594.g001){ref-type="fig"}). Following the sequence corresponding to the partial cassette, there was a 16-bp insertion. The remainder of the sequence matched the wild-type genome starting 3 bps upstream of the PAM and continuing through sequence corresponding to the right homology arm. The 5' end of the sequence from the seventh strain (D6) matched the 5' end of the wild-type sequence until 7 bps upstream of the PAM. At this point, there was a 158-bp insertion corresponding to bps 1496--1653 of the donor DNA. This was followed by sequence corresponding to a partial cassette in which the first 163 bps were deleted. The remaining portion of the cassette was followed by sequence corresponding to the right homology arm. The 167-bp and 163-bp deletions in strains C6 and D6, respectively, removed the first 121 bps (strain C6) and 117 bps (strain D6) of the beta-tubulin promoter upstream of the paromomycin-resistance gene (*aphVIII*) coding sequence. Since these strains were paromomycin resistant, it seems likely that either a) the truncated beta-tubulin promoter retained activity; b) another promoter, such as that of *FAP70*, served as the promoter for the *aphVIII* gene; or c) a functional cassette was inserted at another site in the genome. In any case, in all seven strains, donor DNA was inserted at the intended target site, resulting in an insertional mutation likely to cause disruption of the *fap70* gene.

To determine the effectiveness of TIM for genes other than *FAP70*, we tested the method on the IFT complex-B gene *IFT81*, using *FAP70* as positive control. *IFT81*, which we targeted at exon 3, was chosen for this test because the *ift81*-null mutant is well characterized \[[@pone.0232594.ref027]\] and an excellent antibody to IFT81 is available \[[@pone.0232594.ref029]\]. Initially, we used the same autolysin-treated preparations of cells and targeted either *IFT81* or *FAP70* using a paromomycin-resistance cassette with 50-bp gene-specific homology arms. In two experiments, we obtained efficiencies of 42% and 36% for *IFT81* vs. 85% and 67% for *FAP70* ([Table 1](#pone.0232594.t001){ref-type="table"}, rows 25 and 26). The design of the gRNA is undoubtedly important for efficient mutagenesis, so we next tried a different gRNA for *IFT81*; in this case we obtained mutation efficiencies of 40% for *IFT81* vs. 63% for *FAP70* ([Table 1](#pone.0232594.t001){ref-type="table"}, rows 27 and 28). Finally, we compared the two *IFT81* gRNAs directly, and obtained efficiencies of 30% for the first and 52% for the second ([Table 1](#pone.0232594.t001){ref-type="table"}, rows 29 and 30). It seems likely that the lower mutation rates obtained for *IFT81* represent lower efficiencies of the *IFT81* gRNAs, although one cannot rule out that some genes are inherently less efficiently targeted than others by TIM. In any case, the efficiencies obtained for *IFT81* were sufficiently high to easily identify insertional mutants. The *ift81* mutants that we generated exhibited a palmelloid phenotype--i.e., they failed to hatch from the mother cell wall--matching the phenotype previously reported for an *ift81* null mutant \[[@pone.0232594.ref027]\]. No bands corresponding to IFT81 were detected in western blots of these mutants, confirming disruption of the *IFT81* gene by TIM ([Fig 1C](#pone.0232594.g001){ref-type="fig"}).

To further assess the effectiveness and broader applicability of TIM, we targeted four other genes: *MOT17*, *CDPK13*, and *CEP131*, for which no mutants have yet been reported, and *IFT43*. *MOT17* and *CDPK13* were targeted in the same autolysin-treated batch of cells using *FAP70* as positive control and donor DNA having 50-bp homology arms; mutagenesis efficiencies of 93% and 47% were obtained for *MOT17* and *CDPK13*, respectively, vs. 78% for *FAP70* ([Table 1](#pone.0232594.t001){ref-type="table"}, rows 31--33). *CEP131* was targeted using two different guide RNAs and donor DNA without homology arms, which yielded mutation rates of 41% and 30% ([Table 1](#pone.0232594.t001){ref-type="table"}, rows 34 and 35). *IFT43* also was targeted using donor DNA without homology arms, resulting in a mutation rate of 89% ([Table 1](#pone.0232594.t001){ref-type="table"}, row 36). Therefore, TIM appears to be effective with a wide range of genes. Further characterization of these mutants is ongoing.

The high mutation efficiencies that we obtained with different genes suggested that it might be possible to target two different genes in a single experiment. To test this, we used RNPs and donor DNAs for *IFT81* (Chromosome 7) and *FAP70* (Chromosome 6). These experiments used paromomycin- and hygromycin-resistance cassettes with 50-bp homology arms for *IFT81* and *FAP70*, respectively, and antibiotic-resistant cells were selected on agar plates containing both paromomycin and hygromycin. In three independent experiments, we were able to generate dual mutants with efficiencies of 15%, 3%, and 6% ([Table 1](#pone.0232594.t001){ref-type="table"}, row 37). As expected, the mutation rates for generation of double mutants was much lower than that achieved when targeting only a single gene, but the results clearly demonstrate that two independent genes can be targeted simultaneously using TIM.

Discussion {#sec003}
==========

Efficient mutagenesis of specific nuclear genes has been a long-standing challenge in the *C*. *reinhardtii* research field. Here we addressed this challenge by starting with the briefly described method of Shamoto et al. \[[@pone.0232594.ref023]\] and varying several parameters to determine which are critical and which can be changed as might be desirable for specific circumstances. We also tested the broader applicability of TIM by targeting several different genes.

Many studies are best carried out with cell-walled strains, so we felt that it was imperative that a general method for targeted insertional mutagenesis be applicable to, and efficient for, such strains. This is indeed the case for TIM, which works well with the cell-walled strains CC-125 and CC-5415. However, we found that it was critical to remove the cell walls by autolysin treatment prior to delivery of the RNP by electroporation. Cell-wall removal by autolysin is usually, if not always, done for delivery of DNA into cells by the glass-bead method \[[@pone.0232594.ref028]\], but in previous studies we have found that it is not necessary for electroporetic transformation with DNA \[e.g., [@pone.0232594.ref025]--[@pone.0232594.ref027]\]. It is possible that cell-wall removal is specifically required for electroporation of RNP, as opposed to DNA, into cells. In any case, we recommend that cells be used for TIM only if the autolysin treatment is effective as assessed by treatment of cells with detergent (see [Materials and Methods](#sec004){ref-type="sec"}). If the majority of cells do not lyse, then the experiment should be jettisoned and a new batch of autolysin prepared.

It also was imperative that the method be applicable to different strains, so that one could use any strain with a genetic background advantageous for a particular approach or experiment. TIM was highly efficient with the two strains tested here, so it is likely also to work well with many other strains.

The ability to choose between selectable markers is important if mutants are to be generated in strains already carrying an antibiotic-resistance gene (e.g., a previously generated mutant). We tested two different antibiotic-resistance genes--*aphVIII* from *S*. *rimosus* and *aph7"* from *S*. *hygroscopicus*--and observed similarly high mutagenesis rates with both. It is likely that other selectable markers also will work with TIM. The ability to use different antibiotic-resistance genes also allowed us to simultaneously target two different genes and then select for double mutants resistant to both antibiotics.

Surprisingly, we found that high efficiencies of insertional mutagenesis could be achieved using insertion cassettes without homology arms. Apparently, after the double-stranded break is generated by the RNP, the cell's DNA-repair machinery joins the broken ends of the chromosome to the ends of the cassette (*sans* homology arms) often enough that correctly targeted insertional mutants can be readily selected under our conditions. However, in careful comparisons, we found that the percent of antibiotic-resistant strains with correctly targeted insertions increased with the use of 25-bp homology arms and was even greater with the use of 50-bp homology arms. Therefore, we recommend including homology arms, especially when targeting a new gene for which design of the gRNA may not be optimized.

The TIM method described here accommodates considerable flexibility with regard to method of cell growth (continuous light vs. a light-dark cycle; liquid medium vs. agar plates), culture cell density, density of cells in the electroporation chamber, and method of delivering macromolecules to the cells (electroporation vs. glass-bead method). Assuming that the high efficiencies observed with the six genes targeted here extend to other genes, there may be little need for further improvement. However, because the efficiency of a new gRNA cannot be predicted with certainty, an even more effective protocol might make the difference between success and failure. Any improvement to the protocol might also result in higher efficiencies when generating double mutants. To this end, future work might examine the effect of increasing the concentration of the RNP and donor DNA, increasing the length of the homology arms on the antibiotic-resistance cassettes beyond 50 bps, or varying the ratio of RNP to donor DNA.

It also would be interesting to determine if a Cpf1 RNP \[[@pone.0232594.ref017]\] could replace the Cas9 RNP used in our method. Cpf1 recognizes a different PAM sequence than Cas9. If successful, the use of Cpf1 would provide researchers with a wider variety of target sites for any given gene \[[@pone.0232594.ref030]\]. Additionally, Cpf1 generates a staggered DSB, whereas Cas9 generates a blunt DSB. Staggered DSBs may be more efficient than blunt DSBs in exogenous DNA insertion. This could further increase the efficiency of both the single- and dual-target experiments.

In many organisms, it is possible to precisely edit (as opposed to disrupt) genes via CRISPR/Cas9-mediated HDR, and there currently is much interest in developing efficient methods for such precise gene editing in *C*. *reinhardtii* \[e.g., [@pone.0232594.ref017], [@pone.0232594.ref018], [@pone.0232594.ref020]\]. However, if one has a *C*. *reinhardtii* null mutant, such as those generated by TIM, that mutant usually can be "rescued" by transformation with constructs designed to express the affected protein with engineered changes ranging from a single amino-acid substitution to addition of an affinity or fluorescent tag \[e.g., [@pone.0232594.ref027], [@pone.0232594.ref031]--[@pone.0232594.ref040]\]. For non-essential genes, the ease with which this can be accomplished in *C*. *reinhardtii* makes this approach a reasonable alternative to precise gene editing by CRISPR/Cas9-mediated HDR.

TIM can result in a range of mutations in the target gene, as evidenced by the different band patterns observed in the PCR screen shown in [Fig 1A](#pone.0232594.g001){ref-type="fig"}. Sequencing the mutations from several *fap70* mutants that had yielded large bands in our PCR screen revealed that most had clean insertions of the donor DNA at the target site, and all had large (\~1.7-kb) insertions likely to cause disruption of the gene. The *ift81* mutants that we characterized also were functionally null. However, in detailed analysis of several insertional mutants obtained from the CLiP library (8), we found that some still expressed sequence from either the N- or C-terminus of the mutated protein (40). Therefore, for any mutant created by insertional mutagenesis, it is advisable to characterize the mutant at the protein level before concluding that it is truly null.

In summary, we have tested several parameters and conditions for TIM, identifying those that are and are not critical for success. We have used TIM to target six different genes with eight different gRNAs and achieved highly efficient mutagenesis (30--90%) in each case. Therefore, similar results are likely to be obtained with many other genes. The protocol that we recommend based on these experiments is detailed in the Materials and Methods section.

Materials and methods {#sec004}
=====================

Strains and media {#sec005}
-----------------

*C*. *reinhardtii* strains CC-620 (*nit1*, *nit2*, *mt+*), CC-621 (*nit1*, *nit2*, *mt-*), 137c (CC-125; *nit1*, *nit2*, *mt+*) and g1 (CC-5415; *nit1*, *agg1*, *mt+*) (Chlamydomonas Resource Center, <https://www.chlamycollection.org/>) were utilized in this study. Media used were: Tris-acetate-phosphate (TAP) medium \[[@pone.0232594.ref041]\]; M (minimal) medium I \[[@pone.0232594.ref042]\] modified to contain 0.0022 M KH~2~PO~4~ and 0.00171 M K~2~HPO~4~ \[[@pone.0232594.ref043]\]; M-N medium (modified M medium lacking NH~4~NO~3~).

gRNA and donor DNA design {#sec006}
-------------------------

gRNAs for *IFT81* (first gRNA), *IFT43*, *MOT17*, and *CDPK13* were designed using Integrated DNA Technology's (IDT) online custom Alt-R^®^ CRISPR-Cas9 guide RNA tool (<https://www.idtdna.com/site/order/designtool/index/CRISPR_CUSTOM>). gRNAs for *FAP70*, *IFT81* (second gRNA), and *CEP131* were designed using the CRISPR-direct website (<http://crispr.dbcls.jp>) \[[@pone.0232594.ref044]\]. The paromomycin-resistance cassette was amplified from the pKS-aphVIII-lox aphVIII plasmid (Chlamydomonas Resource Center), while the hygromycin-resistance cassette was amplified from the pHyg3 plasmid \[[@pone.0232594.ref045]\]. All CRISPR RNAs (crRNAs) and primers used in this study are listed in [S1 Table](#pone.0232594.s003){ref-type="supplementary-material"}.

Preparation of Cas9/gRNA RNP {#sec007}
----------------------------

IDT Alt-R^®^ CRISPR-Cas9 crRNA (10 μL, 40 μM) was annealed with IDT Alt-R^®^ CRISPR-Cas9 tracrRNA (10 μL, 40 μM) by heating to 95°C for 2 minutes and then cooling slowly to room temperature. Two microliters of annealed gRNA were incubated with 5 μg of IDT Alt-R^®^ S.p.Cas9 Nuclease V3 in IDT RNA duplex buffer at 37°C for 15 minutes in a final volume of 10 μL.

Autolysin preparation {#sec008}
---------------------

Aliquots (250 μL/dish) of CC-620 and CC-621 cell cultures were separately plated on 10-cm culture dishes containing TAP medium + 1.5% agar. Two plates for each cell line were grown under a 14:10 light:dark cycle until the cells reached confluency (usually 4--7 days depending on the amount of starting cells). Cells from each strain were scraped from the agar plates, transferred to 20 mL of M-N medium, and resuspended by vortexing. Cells were collected by centrifugation at 1819 x g for 5 min, resuspended in 20 mL fresh M-N medium, and incubated in a 250-mL Erlenmeyer flask under constant light with very gentle shaking until gametes formed (usually 3--5 hours). Gametes of opposite mating types were mixed and left under constant light for 5 minutes without agitation. The mixture was centrifuged at 11,950 x g for 10 minutes at 4°C to remove cells, and the supernatant harvested, filtered through a 0.45-μm filter (Corning^™^ Centrifuge Tube Top Vacuum Filter 430314), and stored long-term at -80°C.

Delivery of Cas9/gRNA RNP and donor DNA {#sec009}
---------------------------------------

Cells were grown on TAP plates for 3--5 days (either under 14:10 light:dark cycle or under constant light). Cells were transferred from plates to 6 mL of autolysin-containing solution (see the section above) for 1 hour at room temperature to remove their cell walls. To test the effectiveness of the autolysin treatment, a small aliquot of cells (\~10 μL) was mixed with an equal volume of 0.5% Triton-X100 and observed under a phase microscope using a 16x-objective lens. If the majority of cells had undergone lysis, the autolysin treatment was considered effective. Multiple treatments with autolysin might be needed to achieve a high degree of cell-wall removal. Following cell-wall removal, cells (still in autolysin solution) were incubated at 40°C for 30 minutes with gentle agitation, a treatment that Greiner et al. (18) concluded was beneficial for processes related to CRISPR/Cas9 activity, DNA repair, DNA integration, and/or homologous recombination. To completely remove the autolysin, cells were collected by centrifugation at 1819 x g, washed once with 10 mL TAP + 2% sucrose, and then resuspended in TAP + 2% sucrose at a concentration of 2.0--7.0x10^8^ cells/mL. Ten μL of Cas9/gRNA RNP and 2 μg of donor DNA were mixed with approximately 110 μL of concentrated cells to give a final volume of 125 μL. The RNP and donor DNA was then delivered into the cells either by electroporation or the glass-bead method. For electroporation, the mixture was electroporated in a Bio-Rad 0.2-cm gap cuvette using a BTX ECM 600 at 350V, 25Ω, and 600 μF \[[@pone.0232594.ref046]\]. The cuvette was then incubated immediately at 16°C for 1 hour.

For the experiment to test the effect of growing cells in liquid culture, 250-mL Erlenmeyer flasks containing about 125 mL of liquid TAP medium were inoculated with 1 mL containing 1X, 5X, or 25X number of cells. Cultures were grown for two days with a 14-hour light:10-hour dark cycle and shaking at \~100 rpm until reaching densities of 6.6X10^5^ to 1.33 X 10^7^ cells/mL. Cells were collected by centrifugation and treated with autolysin as in the previous paragraph.

For the glass-bead method \[[@pone.0232594.ref028]\], autolysin-treated cells, RNP, and donor DNA were transferred to a 15-mL tube with 0.3 g of glass beads (0.45--0.52-mm diameter) and vortexed immediately at top speed on a Vortex Genie 2 (Scientific Industries) for 15 seconds, rested for 10 seconds, then vortexed again at top speed for 10 seconds.

Following either of the delivery methods, the cells were transferred to 10 mL fresh TAP + 2% sucrose in a 15-mL tube and gently rocked under dim light for 24 hours at room temperature. The cells were then collected as above, mixed with 3.5 mL TAP + 0.5% agar (\< 42°C), and pipetted onto TAP + 1.5% agar plates containing either 10 μg/mL paromomycin, 10 μg/mL hygromycin, or both. The 0.5% agar was allowed to solidify at room temperature and the plates placed under a 14:10 light:dark cycle at 23°C for one week.

Genotyping and sequencing of potential mutants {#sec010}
----------------------------------------------

Antibiotic-resistant cells were picked into 150 μL M media in 96-well plates and were grown in a 14:10 light:dark cycle for 2--4 days. Ten μL of cell culture were mixed with 50 μL of 10 mM EDTA and then heated to 100°C for 20 minutes to generate crude genomic DNA for screening cell lines by PCR. Primer sequences used to screen the cell lines are listed in [S1 Table](#pone.0232594.s003){ref-type="supplementary-material"}. The housekeeping gene *RACK1* \[[@pone.0232594.ref047]\] or mating-type-plus specific gene *FUS1* \[[@pone.0232594.ref048]\] was used as positive control. Mutation rate was the percent of antibiotic-resistant cell lines in which the targeted gene was disrupted as determined by PCR ([Fig 1A](#pone.0232594.g001){ref-type="fig"}). NCBI and Phytozome 12 identifications for all targeted genes are listed in [S2 Table](#pone.0232594.s004){ref-type="supplementary-material"}.

For sequencing of *fap70* mutations, PCR bands were gel purified using the Zymoclean gel DNA recovery kit (Zymo Research) according to the manufacturer's instructions. The purified DNA was sent for sequencing using the primers FAP70 F, FAP70 R, and AphVIII-1 ([S1 Table](#pone.0232594.s003){ref-type="supplementary-material"}).

Western blotting {#sec011}
----------------

Wild-type cells and *IFT81* mutants were grown in liquid M medium in a 24-well plate for 5 days and were harvested for preparation of whole-cell extracts. Briefly, cells were collected by spinning in an Eppendorf tabletop centrifuge at 845 x g for 5 minutes. The cell pellet was resuspended in 5x-denaturing sample buffer (50 mM Tris, pH 8.0, 160 mM DTT, 5 mM EDTA, 50% sucrose, and 5% SDS), heated to 90°C for 5 min, then passed through a 26-gauge needle six times. Equal amounts of protein from control and test samples were subjected to SDS-PAGE and transferred to Immobilon P (EMD Millipore, Billerica, MA) membrane for subsequent analysis. Membranes were probed with the following antibodies at the indicated dilutions: mouse monoclonal anti-IFT81 (1:400) \[[@pone.0232594.ref029]\] and anti- ATP synthase β subunit (1:100,000; Agrisera, Vännäs, Sweden, catalog number AS05 085).

Supporting information {#sec012}
======================

###### Sequences from *fap70* mutants, donor DNA, and wild type.

(DOCX)

###### 

Click here for additional data file.

###### Alignment of sequences of donor DNA, wild-type DNA, and DNA from *fap70* mutants C6 and D6.

(DOCX)

###### 

Click here for additional data file.

###### List of crRNA and primer sequences.

(DOCX)

###### 

Click here for additional data file.

###### Gene identifications.

(DOCX)

###### 

Click here for additional data file.

###### 

(PDF)

###### 

Click here for additional data file.
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1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes
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2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: N/A

Reviewer \#2: N/A

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes
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4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This manuscript reports a major advance in Chlamydomonas molecular biology, and will be of great interest to the large and growing community of users who employ Chlamydomonas as a model system. Although it is based on previously published work, cited appropriately, it very carefully works through a large number of important parameters, and in careful fashion establishes the most favorable conditions for gene disruption using Cas9RNPs and CRISPR. The experiments are carefully designed and carefully reported.

The usefulness of the manuscript, however, would be greatly enhanced by an improved presentation of figure 1. First, although the discussion refers to red asterisks and arrows, I do not see these. As the figure is drawn and described this reviewer had a hard time understanding exactly what was done. As drawn, at least to my eyes, the expected PCR product from a perfect insertion would not be centered, or even overlap, the RNP cut site. The \"homology arms\" added to the antibiotic resistance cassette are not delineated on the figure. Is the left homology arm to the left of the green box? Where are the black arrows representing the homology arms on the top line? Are they in the blue box (target site) or just outside. Perhaps my confusion comes from the labeling of the green boxes on the second and third lines. The second box refers to the antibiotic resistance cassette with homology arms, and the third line just refers to the antibiotic resistance cassette. The boxes, however, are the same size. On the NHEJ side of the figure, what is the orange box? Is it formed from the remaining parts of the target?

It would be very helpful for understanding the nature of the insertions to have some of the PCR products sequenced and compared to the starting genome. Were the cuts precise, or ragged? Some of the ca. 2 kb bands appear to be doublets, or somewhat offset from the others. Alternatively a second round of PCR using a primer within the antibiotic resistance gene and one of the outside primers would be useful for characterizing the inserts. Of particular interest with regard to the question of the structure of insertion sites is the experiment on line 18 of Table 1. Even without added homology arms, the insertion cassette was present at the cut site in 20 of 48 drug-resistant transformants. These insertions have to be a result of NHEJ, because there is no homology to target the insertion event. Thus in almost half of events cells chose to \"grab\" the ends of the cassette to fill that gap rather than just grabbing the broken ends of the chromosome. If this observation held with more experiments on other genes, a user of this technique might not choose to \"customize\" their cassette with homology arms if targeting was achieved just choosing by the specificity of the Cas9 cut site.

A smaller improvement in the manuscript that should be included is to drop the mention of the experiment on rows 12 and 13 of Table 1. Because autolysin treatment of these cells was ineffective, as noted in the legend, there is no information to be gained about whether 24 vs. 48 hours of growth before selection is preferred.

Reviewer \#2: This manuscript describes methods for targeted insertional mutagenesis (TIM) in the unicellular green alga, Chlamydomonas reinhardtii. The organism has proved to be an important model system for studies of multiple processes and organelles, including cilia and flagella, the cell cycle, fertilization, photosynthesis, and phototaxis. As the authors indicate, an excellent mutant library is now available for the community, but a reliable, efficient method for targeted mutagenesis has been needed for study of many genes not available in the library. The manuscript provides compelling evidence that by use of these optimized methods, investigators can now generate desired mutants at high efficiency. The manuscript is especially well-written and was a pleasure to read.

The only minor suggestion I have is that the authors clarify the steps in their procedure in which cells are in the M-N medium. LIne 317 states "During experiments, cells were placed in M-N medium (modified M medium lacking NH4NO3)." Apparently, the autolysin is in M-N medium, and during autolysin treatment, cells will be in M-N. But, according to the text, before autolysin treatment the cells are in growth medium, and after autolysin, the cells are washed from that solution into other media.
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\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]
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Reviewer \#1:

The usefulness of the manuscript, however, would be greatly enhanced by an improved presentation of figure 1. First, although the discussion refers to red asterisks and arrows, I do not see these.

Response: To make it easier to find the asterisks and arrows, we now specify in the legend that they are "on the right side of the gel." We also have changed their color to black and have made them slightly larger.

As the figure is drawn and described this reviewer had a hard time understanding exactly what was done. As drawn, at least to my eyes, the expected PCR product from a perfect insertion would not be centered, or even overlap, the RNP cut site. The \"homology arms\" added to the antibiotic resistance cassette are not delineated on the figure. Is the left homology arm to the left of the green box? Where are the black arrows representing the homology arms on the top line? Are they in the blue box (target site) or just outside. Perhaps my confusion comes from the labeling of the green boxes on the second and third lines. The second box refers to the antibiotic resistance cassette with homology arms, and the third line just refers to the antibiotic resistance cassette. The boxes, however, are the same size.

Response: We are grateful for the feedback on the shortcomings of the original figure. The schematic diagram of Figure 1A has now been modified in several ways. Importantly, we have now drawn the diagrams in the first and second rows to the same scale as those in the third row. We now show the positions of the homology arms on the donor DNA, and of the corresponding sequences on the genome; these are marked with L for left and R for right. A branch has been added to the arrow in the (left) pathway to indicate how the antibiotic-resistance cassette is inserted into the genome in that pathway. We have added black arrows to indicate the positions of the primers used for screening.

On the NHEJ side of the figure, what is the orange box? Is it formed from the remaining parts of the target?

Response: In the right pathway, we have changed "NHEJ causing indel mutation" to "End joining without integration of donor DNA," which is more inclusive of the events that might occur in this pathway. The orange box was indeed meant to indicate the remaining parts of the target; we have now replaced it with a smaller box, colored blue to match the target site from which it is derived. A small white box is inserted into the small blue box to indicate that if an indel occurs in this pathway, it is small and will not change the size of the PCR product. Arrows with labels have been added to show the positions of the primers relative to the target site.

The figure legend has been revised to reflect these changes, which have improved the figure immensely.

It would be very helpful for understanding the nature of the insertions to have some of the PCR products sequenced and compared to the starting genome. Were the cuts precise, or ragged? Some of the ca. 2 kb bands appear to be doublets, or somewhat offset from the others. Alternatively a second round of PCR using a primer within the antibiotic resistance gene and one of the outside primers would be useful for characterizing the inserts.

Response: We appreciate the reviewer bringing this to our attention. We also were curious about the nature of the mutations, so we randomly picked and sequenced seven larger PCR bands from fap70 mutants generated using 50-bp homology arms. In wild type, sequence corresponding to the left homology arm of the donor DNA is 27 bps upstream of the PAM, while sequence corresponding to the right homology arm is 3 bps downstream from the PAM. Five of the mutants had sequences identical to that of wild type except that the 33 bps between the sequences corresponding to the homology arms were replaced with an intact paromomycin-resistance cassette, as expected for HDR. In each of the other two mutants, partial cassette sequence with 5' and 3' indels was similarly present between regions corresponding to the left and right homology arms. We have added a paragraph to the Results section describing the sequencing data and briefly discuss the new data in the Discussion section. We have added the sequencing method to the Methods and Materials, and have added one primer used in sequencing to Table S1. We also have added two supplementary files (Appendix S1 reporting the mutant sequences and Appendix S2 showing the alignment of the sequences) for readers who might be interested in the details. The data do not enable conclusions regarding whether the cuts were precise or ragged. However, the sequencing did confirm the insertion of our donor DNA at the intended target site.

Of particular interest with regard to the question of the structure of insertion sites is the experiment on line 18 of Table 1. Even without added homology arms, the insertion cassette was present at the cut site in 20 of 48 drug-resistant transformants. These insertions have to be a result of NHEJ, because there is no homology to target the insertion event. Thus in almost half of events cells chose to \"grab\" the ends of the cassette to fill that gap rather than just grabbing the broken ends of the chromosome. If this observation held with more experiments on other genes, a user of this technique might not choose to \"customize\" their cassette with homology arms if targeting was achieved just choosing by the specificity of the Cas9 cut site.

Response: We agree with the reviewer that these insertions are most likely a result of NHEJ. However, with all due respect, the fact that 20 out of 48 drug-resistant transformants had insertions at the target site does not mean that "in almost half of events cells chose to 'grab' the ends of the cassette to fill that gap rather than just grabbing the broken ends of the chromosome." The other 28 antibiotic-resistant strains that did not pass our PCR screen presumably represent a subset of cells in which the antibiotic-resistance cassette integrated elsewhere in the genome. These cells may or may not have been cut at the target site by the RNP. Additionally, we do not know the fraction of cells that were cut at the target site and did not undergo insertion of donor DNA. This fraction could have been large, in which case only a small (but unknown) fraction of the cells with double-strand breaks at the target site underwent integration of the donor DNA lacking homology arms. Therefore, it is not possible to determine from the data what fraction of cells with double-strand breaks chose to grab the ends of the cassette to fill the gap.

Nevertheless, the fact that we were able to select for many correctly targeted insertional mutants even in the absence of homology arms is important. We have revised the relevant paragraph of the Discussion to highlight this point and the evidence that inclusion of homology arms is advantageous. We thank the reviewer for calling this to our attention.

A smaller improvement in the manuscript that should be included is to drop the mention of the experiment on rows 12 and 13 of Table 1. Because autolysin treatment of these cells was ineffective, as noted in the legend, there is no information to be gained about whether 24 vs. 48 hours of growth before selection is preferred.

Response: We thank the reviewer for this suggestion. Rows 12 and 13 of original Table 1 have been deleted, and the subsequent rows renumbered accordingly in both the table and text. The paragraph discussing the results of the experiment in original rows 12 and 13 has been deleted.

Reviewer \#2:

The only minor suggestion I have is that the authors clarify the steps in their procedure in which cells are in the M-N medium. LIne 317 states "During experiments, cells were placed in M-N medium (modified M medium lacking NH4NO3)." Apparently, the autolysin is in M-N medium, and during autolysin treatment, cells will be in M-N. But, according to the text, before autolysin treatment the cells are in growth medium, and after autolysin, the cells are washed from that solution into other media.

Response: The reviewer's interpretation is correct, and we thank him or her for pointing out that we introduced confusion with the wording in the original Materials and Methods. We have now changed the quoted sentence to simply "Media used are: Tris-acetate-phosphate (TAP) medium \[41\]; M (minimal) medium I \[42\] modified to contain 0.0022 M KH2PO4 and 0.00171 M K2HPO4 \[43\]; M-N medium (modified M medium lacking NH4NO3)." Under "Autolysin preparation," we state that cells were scrapped from plates and resuspended in M-N medium until gametes formed. As the reviewer notes, autolysin was in M-N medium (this should be clear from the description of "Autolysin preparation"), and cells were briefly treated with this solution to remove their cell walls (described under "Delivery of Cas9/gRNA RNP and donor DNA").

Finally, we have moved the final paragraph of the Results section to the end of the Discussion, which is a more appropriate place for it, improved what was the final paragraph but is now the penultimate paragraph of the Discussion, and made a few very minor changes elsewhere, e.g., to report which exons were targeted and to improve syntax or clarity.

###### 

Submitted filename: Response to Reviewers.docx

###### 

Click here for additional data file.
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Reviewer \#1: All comments have been addressed
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2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes
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3\. Has the statistical analysis been performed appropriately and rigorously?
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4\. Have the authors made all data underlying the findings in their manuscript fully available?
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